Editas Medicine Inc Revenue Growth Rates (EDIT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Editas Medicine Inc   (NASDAQ: EDIT)
 

EDIT's Revenue Growth by Quarter and Year

Editas Medicine Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EDIT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 11.89
1st Quarter March 2.83
FY 14.72

EDITs Annual Revenue
Editas Medicine Inc 's Revenue in the fiscal year 2025 $ 40.52 millions
Editas Medicine Inc 's Revenue in the fiscal year 2024 $ 32.31 millions
Editas Medicine Inc 's Revenue in the fiscal year 2023 $ 78.12 millions
Editas Medicine Inc 's Revenue in the fiscal year 2022 $ 19.71 millions
Editas Medicine Inc 's Revenue in the fiscal year 2021 $ 25.54 millions




EDIT Revenue second quarter 2026 Y/Y Growth Comment
Editas Medicine Inc reported Revenue surge of 232.12% year on year in the second quarter 2026, to $ 11.89 millions, this is lower than Editas Medicine Inc 's recent average Revenue surge of 812.82%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Revenue growth. While Editas Medicine Inc ' s Revenue doubling of 232.12% ranks overall at the positon no. 128 in the second quarter 2026.


EDIT Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -19.18 % -49.03 % 818.2 %
3rd Quarter September - 12466.67 % -98.88 % 13250 %
2nd Quarter June 232.12 % 601.96 % -82.35 % -54.56 %
1st Quarter March -39.27 % 308.77 % -88.43 % 45.49 %
FY   - 25.37 % -58.63 % -

Financial Statements
Editas Medicine Inc 's second quarter 2026 Revenue $ 11.89 millions EDIT's Income Statement
Editas Medicine Inc 's second quarter 2025 Revenue $ 3.58 millions Quarterly EDIT's Income Statement


EDIT Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 228.12 % 50916.67 % 1024.53 %
3rd Quarter September - 110.61 % -88.24 % 84.78 %
2nd Quarter June 320.14 % -23.18 % -55.26 % -70.66 %
1st Quarter March -88.56 % -84.78 % -98.1 % 50.61 %
FY (Year on Year)   - 25.37 % -58.63 % -


Back to EDIT Growth rate Comparisons >> Back to EDIT Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #41
Overall #128

Revenue Y/Y Growth Statistics
High Average Low
12604.76 % 812.82 % -99.32 %
(Sep 30 2020)   (Sep 30 2021)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #41
Overall #128
Revenue Y/Y Growth Statistics
High Average Low
12604.76 % 812.82 % -99.32 %
(Sep 30 2020)   (Sep 30 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Editas Medicine Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
50072.13 % 1589.83 % -99.34 %
(Dec 31 2024)  


EDIT's II. Quarter Q/Q Revenue Comment
Editas Medicine Inc achieved in the II. Quarter 2026 below company average Revenue doubling of 320.14% quarter on quarter, to $ 11.89 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -23.18% in the II. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Editas Medicine Inc 's Revenue growth quarter on quarter, overall rank is 64.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #26
Overall #64
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #26
Overall #64
Revenue Q/Q Growth Statistics
High Average Low
50072.13 % 1589.83 % -99.34 %
(Dec 31 2024)  


EDIT's II. Quarter Q/Q Revenue Comment
Editas Medicine Inc achieved in the II. Quarter 2026 below company average Revenue doubling of 320.14% quarter on quarter, to $ 11.89 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -23.18% in the II. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Editas Medicine Inc 's Revenue growth quarter on quarter, overall rank is 64.


Editas Medicine Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 47.01 $ 38.69 $ 40.52 $ 46.38 $ 38.90
Y / Y Revenue Growth (TTM) 20.83 % 7.97 % 25.39 % -24.89 % -41.97 %
Year on Year Revenue Growth Overall Ranking # 3601 # 1225 # 2390 # 0 # 41
Seqeuential Revenue Change (TTM) 21.48 % -4.51 % -12.64 % 19.23 % 8.55 %
Seq. Revenue Growth (TTM) Overall Ranking # 1675 # 412 # 2374 # 0 # 2086


Cumulative Revenue growth Comment
Although Editas Medicine Inc 's Annual Revenue growth year on year were below company's average 75.6% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 20.83% year on year, from 7.97% in Mar 31 2026.

In the Healthcare sector 488 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1225 to 3601.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 33
Healthcare Sector # 489
Overall # 3601

Revenue TTM Y/Y Growth Statistics
High Average Low
537.6 %
 75.6 %
-73.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 268
S&P 500 # 1675
Cumulative Revenue growth Comment
Although Editas Medicine Inc 's Annual Revenue growth year on year were below company's average 75.6% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 20.83% year on year, from 7.97% in Mar 31 2026.

In the Healthcare sector 488 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1225 to 3601.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 33
Healthcare Sector # 489
Overall # 3601

Revenue TTM Y/Y Growth Statistics
High Average Low
537.6 %
75.6 %
-73.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 268
S&P 500 # 1675




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EDIT's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Regenxbio Inc 405.73%$ 405.731 millions
Insmed Inc393.78%$ 393.775 millions
Omeros Corporation387.10%$ 387.096 millions
Catheter Precision Inc 380.66%$ 380.660 millions
Macrogenics Inc 377.97%$ 377.974 millions
Vireo Growth Inc.335.47%$ 335.470 millions
Dianthus Therapeutics Inc 294.30%$ 294.301 millions
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions


About Editas Medicine Inc Revenue Growth Rates (EDIT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Editas Medicine Inc (CIK 1650664).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001650664-26-000083
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Editas Medicine Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.